<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03152422</url>
  </required_header>
  <id_info>
    <org_study_id>ERC PoC 713601-uPROPHET</org_study_id>
    <nct_id>NCT03152422</nct_id>
  </id_info>
  <brief_title>Urinary Proteomics in Predicting Heart Transplantation Outcomes</brief_title>
  <acronym>uPROPHET</acronym>
  <official_title>Urinary Proteomics in Predicting Heart Transplantation Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KU Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      uPROPHET aims to validate urinary proteomics for risk stratification and monitoring graft
      performance is recipients of heart transplants
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proof of concept underlying uPROPHET rests on the EPLORE findings that capillary
      electrophoresis coupled with high-resolution mass-spectroscopy reproducibly identified unique
      urinary proteomic (UP) signatures associated with subclinical left ventricular dysfunction,
      renal impairment and adverse cardiovascular outcomes. Consensus criteria currently applied
      for the selection of patients for heart transplantation (HTx) leave an inconvenient margin of
      uncertainty, because of the unpredictable course of the disease and the shortage of donor
      hearts. Furthermore, monitoring graft function and adjusting immunosuppression remain major
      challenges after HTx. Endomyocardial biopsies, up to 20 in the first year after HTx, are the
      standard approach to detect graft rejection, but require an invasive risk-carrying procedure.
      uPROPHET aims to develop UP profiling: (1) as a prognostic tool helpful in selecting
      terminally ill heart failure patients for HTx with the greatest probability of survival while
      adding a maximum of high-quality years to life; and (2) as an instrument to monitor graft
      performance and immune system activity and to manage immunosuppression. The new UP
      classifiers will be initially validated by demonstrating analogy between the proteomic
      profiles in urine and tissue samples of explanted hearts.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Actual">May 8, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>Patients were followed up from the date of first urine sampling until death or censoring on the date of the last available follow-up visit (median 4 years). Events will be reported at study completion.</time_frame>
    <description>This endpoint is available in the hospital records</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft performance</measure>
    <time_frame>Patients were followed up from the date of first urine sampling until death or censoring on the date of the last available follow-up visit (median 4 years). Events will be reported at study completion.</time_frame>
    <description>Monitoring using endomyocardial biopsies and hemodynamic measurements</description>
  </secondary_outcome>
  <enrollment type="Actual">352</enrollment>
  <condition>Heart Transplantation</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Urinary proteomics</intervention_name>
    <description>Urinary proteomics for risk stratification and graft monitoring in recipients of a heart transplant</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        End-stage heart failure due to ischemic, dilated or hypertrophic cardiomyopathy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  End-stage heart failure resistant to treatment

        Exclusion Criteria:

          -  According to guidelines (J Heart Lung Transplant 2010;29:717-27 and J Heart Lung
             Transplant 2016; 35: http://dx.doi.org/10.1016/j.healun.2015.10.023).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jan A Staessen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leuven</affiliation>
  </overall_official>
  <link>
    <url>https://www.kuleuven.be/english/research/EU/p/horizon2020/es/erc/uprophet</url>
    <description>Description of study at the website of the University of Leuven</description>
  </link>
  <results_reference>
    <citation>Huang QF, Trenson S, Zhang ZY, Yang WY, Van Aelst L, Nkuipou-Kenfack E, Wei FF, Mujaj B, Thijs L, Ciarka A, Zoidakis J, Droogné W, Vlahou A, Janssens S, Vanhaecke J, Van Cleemput J, Staessen JA. Urinary Proteomics in Predicting Heart Transplantation Outcomes (uPROPHET)-Rationale and database description. PLoS One. 2017 Sep 7;12(9):e0184443. doi: 10.1371/journal.pone.0184443. eCollection 2017.</citation>
    <PMID>28880921</PMID>
  </results_reference>
  <results_reference>
    <citation>Huang QF, Trenson S, Zhang ZY, Van Keer J, Van Aelst LNL, Yang WY, Nkuipou-Kenfack E, Thijs L, Wei FF, Mujaj B, Ciarka A, Droogné W, Vanhaecke J, Janssens S, Van Cleemput J, Mischak H, Staessen JA. Biomarkers to Assess Right Heart Pressures in Recipients of a Heart Transplant: A Proof-of-Concept Study. Transplant Direct. 2018 Apr 23;4(5):e346. doi: 10.1097/TXD.0000000000000783. eCollection 2018 May.</citation>
    <PMID>29796417</PMID>
  </results_reference>
  <results_reference>
    <citation>Huang QF, Zhang ZY, Van Keer J, Trenson S, Nkuipou-Kenfack E, Yang WY, Thijs L, Vanhaecke J, Van Aelst LNL, Van Cleemput J, Janssens S, Verhamme P, Mischak H, Staessen JA. Urinary peptidomic biomarkers of renal function in heart transplant recipients. Nephrol Dial Transplant. 2019 Aug 1;34(8):1336-1343. doi: 10.1093/ndt/gfy185.</citation>
    <PMID>29982668</PMID>
  </results_reference>
  <results_reference>
    <citation>Huang QF, Van Keer J, Zhang ZY, Trenson S, Nkuipou-Kenfack E, Van Aelst LNL, Yang WY, Thijs L, Wei FF, Ciarka A, Vanhaecke J, Janssens S, Van Cleemput J, Mischak H, Staessen JA. Urinary proteomic signatures associated with β-blockade and heart rate in heart transplant recipients. PLoS One. 2018 Sep 24;13(9):e0204439. doi: 10.1371/journal.pone.0204439. eCollection 2018.</citation>
    <PMID>30248148</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>March 1, 2020</last_update_submitted>
  <last_update_submitted_qc>March 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>KU Leuven</investigator_affiliation>
    <investigator_full_name>Jan A. Staessen</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized data can be made available for scientific purposes via a motivated request to Prof Jan A. Staessen. The request should receive approval by the Ethics Committee of the University Hospitals Leuven.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Currently available until 2025</ipd_time_frame>
    <ipd_access_criteria>Appproval by the Ethics Committee of the University Hospitals Leuven</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

